The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Ocadusertib is under clinical development by Eli Lilly and Co and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 35% phase ...

Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) ...

Although a comparable proportion of Black and non-Black patients discussed surgical weight loss with their provider (9.5% vs ...

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an $ ... is in phase I/II testing as a rescue therapy ...

It was a busy week of high school basketball, giving central Ohio teams a chance to make adjustments. Here are five things we ...

The Fresno Bee ran its Player of the Year, Coach of the Year and The Bee All-Stars that is now Live online. The Bee contacted ...